|1.||Kazimierczuk, Zygmunt: 3 articles (11/2013 - 11/2009)|
|2.||Koronkiewicz, Miroslawa: 1 article (11/2013)|
|3.||Chilmonczyk, Zdzislaw: 1 article (11/2013)|
|4.||Trembley, Janeen H: 1 article (02/2012)|
|5.||Pinna, Lorenzo A: 1 article (02/2012)|
|6.||Korman, Vicci L: 1 article (02/2012)|
|7.||Kren, Betsy T: 1 article (02/2012)|
|8.||Tobolt, Diane K: 1 article (02/2012)|
|9.||Unger, Gretchen M: 1 article (02/2012)|
|10.||Ahmed, Khalil: 1 article (02/2012)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/01/2013 - "In this study, we examined pro-apoptotic and cytostatic effects of three CK2 inhibitors: one known, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) and two new: 2-(4-methylpiperazin-1-yl)-4,5,6,7-tetrabromo-1H-benzimidazole (MPT) and 2-aminoethyleneamino-4,5,6,7-tetrabromo-1H-benzimidazole (AEAT), as well as of certain S-2,3,4,5,6-pentabromobenzylisothiouronium bromides: ZKK-3, ZKK-9, ZKK-13, against the human acute myelogenous leukemia cell line (KG-1). "
|2.||Prostatic Neoplasms (Prostate Cancer)
11/01/2011 - "COX-2 expression and cell viability decreased upon selective inhibition of COX-2 with SC-791 or CK2 with 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), both in human colon (HT29-ATCC, HT29-US, DLD-1) and breast (ZR-75) cancer cells, as well as in human embryonic kidney (HEK-293T) cells. "
11/01/2009 - "Here we compared cytotoxic effects of well-known and new CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBB), 4,5,6,7-tetrabromo-1H-benzimidazole (TBI), 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), the related 3-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)propan-1-ol (MB001), 3-(4,5,6,7-tetrabromo-1H-1,2,3-benzotriazol-1-yl) propan-1-ol (MB002), 3-(4,5,6,7-tetrabromo-2H-1,2,3-benzotriazol-2-yl)propan-1-ol (MB003) and also structurally similar to above compounds pentabromobenzylisothiourea (ZKK1) and its derivatives (ZKK2-8) on cultured malignant glioma cells. "
|5.||Colonic Neoplasms (Colon Cancer)
|3.||Small Interfering RNA (siRNA)